Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.80 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL31012285 | 1.00 | KDM4E (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL29519280 | 1.00 | KDM4E (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL28173756 | 0.90 | MAPT (0.82) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL29620666 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL250806 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29386243 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4166 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29519146 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL3253794 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4165 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308208-B2 | Aerosol generating method and device | ALEXZA PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20100294268-A1 | Aerosol Generating Method and Device | ALEXZA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1911481-A2 | Methods and systems of delivering medication via inhalation | Next Safety, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20080078382-A1 | Methods and Systems of Delivering Medication Via Inhalation | HUNTER, CHARLES ERIC | 2008-04-03 | — | — | US | claimed |
| WO-2008036801-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| WO-2008036798-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-1902742-A1 | Methods and systems of delivering medication via inhalation | Next Safety, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20080066739-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20030062042-A1 | Aerosol generating method and device | ALEXZA PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | claimed |
| US-20030051728-A1 | Method and device for delivering a physiologically active compound | ALEXZA PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | claimed |
| EP-3850097-B1 | NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL | UNIV DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2026-02-11 | — | — | EP | disclosed |
| US-12534727-B2 | Target to treat a metabolic disease in an individual | UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2026-01-27 | — | — | US | disclosed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5017618-A | Treatment Of Glaucoma | UNIVERSITY OF FLORIDA (US) | 1991-05-21 | — | — | US | disclosed |
| US-3985897-A | GLAUCOMA | MEAD JOHNSON & COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3933998-A | 4-[2-(Isopropylamino)ethyl]pyrocatechol intraocular pressure lowering process | MEAD JOHNSON & COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534727-B2 | Target to treat a metabolic disease in an individual | MAT1A, MNAT1, NAT10 | ADRB2 4171/4885ADRB1 2848/4885ADRB3 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.